Summary
For 2 weeks 27 patients with hypercalcemia received a standard oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) as the sole agent. Results were grouped according to causes of hypercalcemia and compared with effects of APD in 13 normocalcemic patients with Paget's disease of bone and 7 with osteoporosis. In 12 hypercalcemic patients with osteolytic bone lesions and in the 20 normocalcemic patients, the mean serum calcium decreased to final levels that were subnormal and significantly lower than those obtained after treatment of 8 patients with primary hyperparathyroidism. In 3 patients with myeloma and in 4 tumor patients without bone lesions, serum calcium did not always decrease to the normal range. Implications of these observations for the mechanism of hypercalcemia are discussed.
Similar content being viewed by others
References
Nordin BEC (1976) Plasma calcium and plasma magnesium homeostasis. In Nordin BEC (ed): Calcium, Phosphate and Magnesium Metabolism. Churchill Livingstone, Edinburgh, pp 186–216
Parfitt AM (1979) Equilibrium and disequilibrium hypercalcemia. New light on an old concept. Metab Bone Dis Rel Res 1:270–293
Bijvoet OLM, Hosking DJ, Lemkes HHPJ, Reitsma PH, Frijlink WB (1977) Development in the treatment of Paget's disease. In Talmage RV (ed): Endocrinology of Calcium Metabolism. Elsevier/Excerpta Medica, Amsterdam, pp 48–54
Frijlink WB, Bijvoet OLM, Te Velde J, Heynen G (1979) Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1:799–803
Adami S, Frijlink WB, Bijvoet OLM, O'Riordan JLH, Clemens T, Papapoulos SE (1982) Regulation of calcium absorption by 1,25,dihydroxy-vitamin D—studies of the effects of a bisphosphonate treatment. Calcif Tissue Int 34:317–320
Breukelen FJM van, Bijvoet OLM, Oosterom AT van (1979) Inhibition of osteolytic bone lesions by (3-amino-1-hydroxy-propylidene)-1,1-bisphosphonate (APD). Lancet 1:803–805
Reitsma PH, Bijvoet OLM, Frijlink WB, Vismans FJFE, Breukelen FJM van (1979) Pharmacology of disodium (3-amino-1-hydroxy-propylidene)-1,1-bisphosphonate. Adv Exp Med Biol 128:219–237
Meunier PJ, Chapuy MC, Alexandre C, Bressot C, Edouard C, Vignon E, Mathieu L, Trechsel U (1979) Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet 2:489–492
Siris ES, Sherman WH, Baguiran DC, Schlatterer JP, Osserman EF, Canfield ER (1980) Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N Engl J Med 302:310–315
Douglas DL, Duckworth T, Russel RCG, Kanis JA, Preston DJ, Preston FE, Prenton MA, Woodhead JD (1980) Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet 1:1043–1047
Reitsma PH, Bijvoet OLM, Verlinden-Ooms H (1980) Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int 32:145–157
Lemkes HHPJ, Reitsma PH, Frijlink WB, Verlinden J, Bijvoet OLM (1977) A new diphosphonate: dissociation between effects on cells and mineral in rats and a preliminary trial in Paget's disease. In Massry RG, Ritz E, Rapado A (eds): Homeostasis of Phosphate and Other Minerals. New York, pp 459–469
Prockop DJ, Udenfriend S (1960) A specific method for the analysis of hydroxyproline in tissues and urine. Anal Biochem 1:228–239
Marshall JH (1969) Measurement and models of skeletal metabolism. In Comar CL, Bronner F (eds): Mineral Metabolism, Vol III, Calcium Physiology. Academic Press, New York, pp 1–122
Bijvoet OLM (1977) Kidney function in calcium and phosphate metabolism. In Avioli LV, Krane SM (eds): Metabolic Bone Disease. Academic Press, New York, pp 49–140
Talmage RV, Kraintz FW, Buchanan D (1955) Effect of parathyroid extract and phosphate salts on renal calcium and phosphate excretion after parathyroidectomy. Proc Soc Exp Biol Med 88:600–604
Talmage RV (1956) Studies on maintenance of serum calcium levels by parathyroid action on bone and kidney. Ann NY Acad Sci 64:326–335
Massry SC, Friedler RM, Coburn JW (1973) Excretion of phosphate and calcium. Arch Intern Med 131:828–859
Walser M (1969) Renal excretion of alkaline earths. Mineral Metab 3:235–320, 1969
Froeling PGAM, Bijvoet OLM (1974) Kidney-mediated effects of parathyroid hormone on extracellular homeostasis of calcium, phosphate and acid base balance in man. Neth J Med 17:174–183
Eisenberg E (1965) Effects of serum calcium level and parathyroid extract on phosphate and calcium excretion in hypoparathyroid patients. J Clin Invest 44:942–946
Russell RGG, Fleisch H (1976) Pyrophosphate and diphosphonates. In Bourne GH (ed): The Biochemistry and Physiology of Bone, Vol IV. Academic Press, New York, pp. 61–104
Bijvoet OLM, Frijlink WB, Jie K, van der Linden H, Meyer CJLM, Mulder H, van Passen HC, Reitsma PH, te Velde J, de Vries E, van der Wey JP (1980) APD in Paget's disease. Role of the mononuclear-phagocytic system? Arthritis Rheum 23:1193–1204
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Breukelen, F.J.M., Bijvoet, O.L.M., Frijlink, W.B. et al. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: Observations on regulation of serum calcium. Calcif Tissue Int 34, 321–327 (1982). https://doi.org/10.1007/BF02411261
Issue Date:
DOI: https://doi.org/10.1007/BF02411261